<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05040230</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0287</org_study_id>
    <nct_id>NCT05040230</nct_id>
  </id_info>
  <brief_title>EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome (ICANS)Lay Language</brief_title>
  <official_title>EEG Encephalopathy Patterns in Immune Effectors Cells-associated Neurotoxicity Syndrome : a Prospective Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune effectors cells-associated neurotoxicity syndrome (ICANS) is one of the most clearly&#xD;
      defined acute toxicities after CAR-T cells infusion.&#xD;
&#xD;
      The investigators conducted a prospective cohort study of all patients who received CAR T&#xD;
      cell infusions on the hematology department from Montpellier University Medical Center.&#xD;
&#xD;
      Each patient was assessed between the 6th and 8th day after infusion by a neurological&#xD;
      clinical examination, an electroencephalogram, and a brain MRI.&#xD;
&#xD;
      The aim of the studies is to describe the EEG pattern associated with ICANS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a prospective cohort study of all patients who received CAR T&#xD;
      cell infusions in the hematology department from Montpellier University Medical Center. To be&#xD;
      eligible for enrollment, patients should have to be 18 years of age or older. All the&#xD;
      patients will have histologically confirmed: diffuse large B-cell lymphoma, B-cell acute&#xD;
      lymphoblastic leukemia, follicular lymphoma, or mantle cell lymphoma.&#xD;
&#xD;
      Each patient will have a PET CT before infusion to determine metabolic response status&#xD;
      according to the LUGANO grading classification. All patients will have preconditioning brain&#xD;
      imaging by MRI.&#xD;
&#xD;
      Each patient will be assessed between the 6th and 8th day after infusion by a neurological&#xD;
      clinical examination, an electroencephalogram, and a brain MRI.&#xD;
&#xD;
      Patients will be called back one month later to report any new neurological event and an EEG&#xD;
      was performed if abnormalities were found on the first.&#xD;
&#xD;
      All neurological symptoms documented in daily progress notes will be catalogued. The&#xD;
      investigators will use ASTCT ICANS Consensus Grading for Adults to evaluate neurotoxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>to assess the sensitivity of EEG for diagnosis of ICANS.</measure>
    <time_frame>day 1</time_frame>
    <description>bandwidth of the EEG which will be assessed during the period of study :&#xD;
background frequencies : alpha, theta or delta&#xD;
reactivity on opening the eyes : yes or not&#xD;
organization of background activity : present or absent&#xD;
presence of paroxysmal activities : yes or not</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>to identify a biomarker for ICANS</measure>
    <time_frame>day 1</time_frame>
    <description>to identify a biomarker for ICANS</description>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Immune Effector Cell Encephalopathy</condition>
  <condition>Neurotoxicity</condition>
  <eligibility>
    <study_pop>
      <textblock>
        a prospective cohort study of all patients who received CAR T cell infusions on the&#xD;
        hematology department from Montpellier University Medical Center between September 2020 and&#xD;
        July 2021&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  histologically confirmed: diffuse large B-cell lymphoma, B-cell acute lymphoblastic&#xD;
             leukemia, follicular lymphoma, or mantle cell lymphoma.&#xD;
&#xD;
          -  with infusion of CAR T-cells&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Age &lt; 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Ayrignac, MD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xavier Ayrignac, MD</last_name>
    <phone>631229414</phone>
    <phone_ext>33</phone_ext>
    <email>x-aurignac@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sophie HUBY, MD</last_name>
    <phone>678970501</phone>
    <phone_ext>33</phone_ext>
    <email>sophie.huby27@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Uhmontpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie HUBY, MD</last_name>
      <phone>678970501</phone>
      <phone_ext>33</phone_ext>
      <email>sophie.huby27@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 2, 2021</study_first_submitted>
  <study_first_submitted_qc>September 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 10, 2021</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Diseases</mesh_term>
    <mesh_term>Neurotoxicity Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

